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ABSTRACT 
 
The vitamin A metabolite, retinoic acid (RA), displays pleiotrophic 
activities by virtue of its ability to activate the ligand-inducible 
transcription factors known as retinoic acid receptors (RAR), thereby 
regulating the transcription of multiple target genes. In addition to RAR, 
RA binds in cells to cellular retinoic acid binding proteins (CRABP-I and 
CRABP-II), and it has been established that CRABP-II enhances the 
transcriptional activity of RAR by directly delivering RA from the cytosol 
to the receptor in the nucleus. Among its other biological activities, RA 
displays a growth inhibitory effect in a variety of cancer cells. Growth 
inhibition by this compound may be mediated by three different cellular 
processes: apoptosis, cell cycle arrest, and differentiation. It has been 
reported that, in human mammary carcinoma cells, RA induces growth 
inhibition by triggering apoptosis, cell cycle arrest, or both. The present 
study was undertaken to identify target genes responsible for RA-induced, 
RAR-mediated cell cycle arrest in MCF-7 mammary carcinoma cells, and 
to examine the contribution of CRABP-II to this process. Upon RA 
treatment, MCF-7 cells were arrested in G1 phase. Affymetrix expression 
array data revealed that RA upregulates the expression of several genes 
that control cell cycle progression, including B-cell translocation gene, 
member 2 (BTG2). In accordance with the role of CRABP-II in enhancing 
RAR transactivation, overexpression of CRABP-II augmented RA-
upregulation of the BTG2 transcript level. BTG2 was found to contain a 
functional RAR response element 3,250 bp upstream of the transcription 
start site. Previous studies reported that BTG2 represses transcription of  
 
cyclin D1, a protein that enables G1 to S transition. Indeed, additional 
experiments showed that RA reduced cyclin D1 expression by 50%. 
Taken together, the observations suggest that RA induces cell cycle arrest 
in MCF-7 by directly inducing BTG2 expression. In turn, BTG2 functions 
to reduce cyclin D1 expression, leading to cell cycle arrest in the G1 
phase. 
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1 
CHAPTER ONE 
INTRODUCTION 
 
  Retinoic acid (RA) is an active metabolite of vitamin A introduced 
to the body through diet. Vitamin A in the form of retinyl ester (RE) is 
stored in liver, forming the biggest vitamin A pool (50-80%) of the 
organism. RE stored in the liver becomes hydrolyzed into retinol (ROH). 
Subsequently, retinol-binding protein (RBP) binds ROH intrahepatically 
for release into the bloodstream. ROH is further coupled to transthyretin 
(TTR) to avoid renal clearance. The uptake of ROH by target cells may 
occur via endocytosis through a receptor-independent mechanism of lipid 
membranes (Biesalski and Nohr, 2004). The majority of cellular retinol is 
bound by cellular retinol-binding protein (CRBP), a protein that is 
believed to shuttle retinol to various enzymes that catalyze its metabolism 
(Spinella and Dmitrovsky, 2000). In cells, ROH can be reesterified into 
RE for storage in the liver and extrahepatic tissues. ROH can also become 
oxidized into RA, an active metabolite that serves as a ligand for retinoic 
acid receptor (RAR) to regulate its target gene transcription. In addition to 
RAR, two other proteins, termed cellular retinoic acid binding proteins 
(CRABP-I and CRABP-II) are involved in regulating the biological 
activities of RA. CRABP-II cooperates with RAR in mediating the 
transcriptional activities of RA. This protein binds free RA in the 
cytoplasm and translocates it to the nucleus to channel RA directly to 
RAR (Budhu and Noy, 2002). CRABP-I, on the other hand, has been 
implicated in shuttling RA to P450 enzymes, specifically CYP26, for its 
degradation (Won et al., 2004).  2 
 
1-1  NUCLEAR HORMONE RECEPTORS 
  The superfamily of nuclear hormone receptors is a group of ligand-
inducible transcription factors, which includes receptors for small 
hydrophobic ligands such as steroids, thyroid hormones, and retinoid 
receptors, as well as orphan receptors with unknown ligands. Based on 
evolutionary analysis, the receptors are divided into six different 
subfamilies (Aranda and Pascual, 2001). Class I includes thyroid hormone 
receptor (TR), vitamin D receptor (VDR), peroxisome proliferator 
activated receptor (PPAR), retinoic acid receptor (RAR) and orphan 
receptors. The second subfamily contains retinoid X receptor (RXR) 
among others. Class III represents receptors for classic steroid hormones: 
estrogen, androgen, progesterone, and glucocorticoids. Lastly, the fourth, 
fifth, and sixth subfamilies contain different orphan receptors.  
  All nuclear hormone receptors share a common structure, which is 
divided into five domains: the most variable amino-terminal 
transactivation region, a highly conserved DNA-binding domain (DBD), a 
hinge region, a ligand-binding domain (LBD), and a carboxyl-terminal 
region (Figure 1-1). Each domain confers specific functions in target gene 
transcription (Bastien and Rochette-Egly, 2004). The amino-terminal 
transactivation region is involved in ligand-independent transcriptional 
regulation. The DNA-binding domain binds a specific receptor to 
particular response elements in the promoters of the target genes. Lastly, 
the ligand-binding domain at the carboxyl-terminal region is involved in 
ligand binding, dimerization, and interactions with transcriptional co-
activators.  
  3 
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Figure 1-1 Nuclear Hormone Receptor Structure. All nuclear hormone 
receptors share a common structure, which is divided into five domains: a 
highly variable amino-terminal transactivation region, a well-conserved 
DNA-binding domain (DBD), a hinge-region, a ligand-binding domain 
(LBD), and a carboxyl-terminal region. 
 
Nuclear hormone receptors are direct regulators of transcription 
that function by binding to specific DNA sequences, named hormone 
response elements (HREs), in the promoters of target genes. These 
response elements typically consist of two hexameric motifs, 
PuG(G/T)TCA, spaced by different numbers of nucleotides in different 
orientations which include direct repeats, inverted repeats, and everted 
repeats (Leid et al., 1992). Transcriptional activation by these receptors 
requires either a homodimerization or a heterodimerization (Aranda and 
Pascual, 2001). The class III receptors bind to their specific HREs as 
homodimers while the class I receptors bind to their HREs as 
heterodimers with a common dimerization partner, the retinoid X receptor 
(RXR). In the absence of their ligands, class III receptors associate with 
heat-shock proteins and remain in the cytoplasm. Only upon binding of 
    Transactivation Region 
DNA-Binding Domain 
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 Ligand-Binding Domain 
C-terminal Region 4 
 
ligands, these receptors dissociate from the heat-shock proteins and 
translocate into the nucleus. The activated receptor homodimers then bind 
to their HREs to recruit a complex of co-activators. In turn, these 
coactivators modify chromatin and stabilize the preinitiation complex to 
initiate transcription (Aranda and Pascual, 2001).  
In contrast, class I receptors bind to their HREs as heterodimers. In 
the absence of ligands, receptor dimers recruit co-repressors containing 
histone deacetylase activity, which silences transcription by promoting a 
closed chromatin structure. Upon binding of the ligands, the receptors 
undergo conformational changes resulting in dissociation of the co-
repressors and association of co-activators containing histone 
acetyltransferase activity, which facilitates transcription by opening the 
chromatin structure. In addition, co-activators stabilize the preinitiation 
complex which, in turn, binds to RNA polymerase II to initiate 
transcription of target genes (Aranda and Pascual, 2001). 
 
1-2 RETINOIC  ACID  RECEPTORS 
  The term “retinoids” is used to describe active natural and synthetic 
derivatives of vitamin A. They serve as ligands for the retinoic acid 
receptors (RAR) to regulate target gene transcription. There are three 
separate genes encoding three isotypes of retinoic acid receptor: RARα, 
RARβ, and RARγ. For each receptor isotype, there exist at least two 
isoforms generated by alternative splicing and differential promoter usage 
(Freemantle et al., 2003). RARs display an expression pattern that is both 
developmentally and tissue specific, allowing for the pleiotropic effects of 
retinoids, which include key roles in embryonic development, postnatal 5 
 
development, and in adult life, growth, reproduction, and homeostasis in 
diverse tissues (Freemantle et al., 2003).  
  RAR functions as a heterodimer with RXR. The RAR/RXR 
heterodimer binds to the specific DNA sequences referred to as retinoic 
acid response elements (RAREs). RAREs are typically composed of two 
direct repeats of the hexameric motif PuG(G/T)TCA, separated by either 
2 (DR-2) or 5 (DR-5) basepairs (Leid et al., 1992). RAREs have been 
identified in the promoters of a large number of retinoid-target genes 
(Bastien and Rochette-Egly, 2004). For example, the classical DR-5 was 
found in the promoters of RARβ, CYP26, and several Hox and HNF 
genes. DR-2 elements were identified in the CRABPI and CRABPII 
promoters (Smith et al., 1991; Durand et al., 1992). 
  As a class I receptor, RAR in its heterodimer form with RXR binds 
to DNA and regulates transcription through its association with 
coactivators and repressors depending on the status of its ligand 
availability. Though both RAR and RXR have the ability to recruit 
coactivators on their own, it has been shown that RXR is subordinate to 
its RAR partner in RAR/RXR heterodimers (Roy et al., 1995). This 
phenomenon has been attributed to the inability of RXR to dissociate 
corepressors unless its partner is also liganded. Therefore, in the presence 
of both RAR and RXR ligands, there is a synergy in transcriptional 
activation resulting from the RAR agonist-induced dissociation of 
corepressors and the subsequent binding of coactivators by both partners 
(Bastien and Rochette-Egly, 2004). 
  Once the chromatin decondenses, coactivators dissociate or become 
degraded by the proteasome, thereby allowing retinoid receptors to recruit 6 
 
the transcription machinery via SMCC (Srb and Mediator protein 
containing complex) mediator complex (Malik and Roeder, 2000). The 
mediator then facilitates the formation of preinitiation complex consisting 
of RNA polymerase II and the general transcription factors to begin 
transcription of target genes (Bastien and Rochette-Egly, 2004). The 
ubiquitin-protease system presents another level of control in RAR/RXR 
transactivation. In response to appropriate signals, the substrates such as 
coactivators and the receptors themselves undergo multi-ubiquitination, 
which then become targeted for destruction by the proteasome. The 
system therefore provides a mechanism not only to shut off the 
RAR/RXR activation, but also to modulate the magnitude and the 
duration of retinoid-mediated transcription (Bastien and Rochette-Egly, 
2004). 
 
1-3 CELLULAR  RETINOIC  ACID BINDING PROTEINS 
  Cellular retinoic acid-binding proteins (CRABPs) are small 
intracellular lipid-binding proteins of approximately 15 kDa in size, 
which bind RA with high affinity and selectivity (Noy, 2000). There are 
two CRABPs, designated as CRABP I and CRABP II. The two CRABPs 
display distinct expression profiles across tissues and development stages 
despite a high degree of homology between them. This suggests that they 
do in fact serve their own unique roles in mediating retinoid functions 
(Manor et al., 2003).  
  The specific function of CRABP I in the context of retinoids 
remains to be elucidated. However, it can be inferred from previous 
studies that it may function in concert with cytochrome P450 enzyme, 7 
 
CYP26, to send RA towards its degradation pathway, thereby decreasing 
the intracellular RA concentration. The physiological consequences of 
decreased RA have been studied in the retinoic acid-sensitive human 
squamous cell carcinoma cell line HTB35 by ectopic overexpression of 
CRABP I (Blaese et al., 2003). The study demonstrated that 
overexpression of CRABP I induced a retinoic acid-insensitive phenotype 
resistant to combined treatment of retinoic acid and radiation in contrast 
to the cells expressing a basal level of CRABP I (Blaese et al., 2003). A 
similar study was performed by another group in a head and neck 
squamous cell carcinoma (HNSCC) cell line and demonstrated that the 
expression of the CRABP I resulted in a lower sensitivity to RA treatment 
in comparison with the control in a clonogenic assay (Won et al., 2004). 
Moreover, it showed an increased level of polar metabolites of RA in 
thin-layer chromatography, suggesting RA metabolism. Several groups 
showed in different cell lines that CRABP I expression either decreased or 
did not enhance RAR transactivation (Won et al., 2004; Venepally et al., 
1996). Despite much effort, no direct evidence showing that CRABP I 
expression indeed decreases intracellular RA concentration has been 
reported. Moreover, the mechanism of how CRABP I delivers RA to 
CYP26, if it does, remains to be investigated. 
  On the other hand, the role of CRABP II in context of RAR 
activation has been studied extensively. First, it has been shown that 
CRABP II expression significantly enhances RAR-mediated 
transcriptional activation of a reporter gene in COS-7 cells (Dong et al., 
1999). The study also demonstrated that despite similar binding affinity of 
RA to both CRABP I and CRABP II, functional differences exist between 8 
 
the two binding proteins due to the direct physical interaction between 
CRABP II and RAR. This direct interaction allows RA to be channeled 
from CRABP II to RAR and facilitates the formation of holo-RAR, 
thereby enhancing the transcriptional activity of RAR in cells (Budhu et 
al., 2001). The region of CRABP II that mediates this interaction with 
RAR has been localized to three spatially-aligned amino acid residues, 
Gln75, Pro81, and Lys102, around the ligand-binding pocket of the 
protein (Budhu et al., 2001). The three residues were identified through 
comparison between CRABP I and CRABP II which revealed a sole 
region displaying a dramatic change in electrostatic surface potential. 
Moreover, it has been shown that conferring these three key residues onto 
CRABP I resulted in its ability to channel RA to RAR. Most recently, 
CRABP II has been shown to contain a ligand-responsive nuclear 
localization signal (NLS) in its tertiary structure, which was not apparent 
in its primary sequence (Sessler and Noy, 2004), further supporting the 
idea that CRABP II travels to the nucleus upon ligand binding to channel 
RA to RAR in order to enhance the transcriptional activity of RAR. 
  In accordance of the ability of CRABP II to channel RA to RAR, 
CRABP II has been shown to enhance retinoid function through RAR. 
The functional consequences of CRABP II therefore lie in its ability to 
sensitize cells to retinoic acid. CRABP II overexpression in MCF-7 
mammary carcinoma cells has been shown to dramatically increase their 
sensitivity to retinoic acid-induced growth arrest (Budhu and Noy, 2002). 
An in vivo study was performed using immunodeficient mice, whereby 
the injection of mammary carcinoma SC115 cells stably expressing 
CRABP II was shown to suppress their tumorogenicity compared to the 9 
 
control (Manor et al., 2003). In a similar fashion, the injection of an 
adenovirus expressing CRABP II into mammary carcinomas that 
spontaneously develop in TgN(MMTVneu)202Mul mice exhibited a slowed 
progression in tumor growth and prolonged survival rates (Manor et al., 
2003). Taken together, these studies demonstrate that CRABP II 
sensitizes cells to RA both in vitro and in vivo for RAR activation, 
thereby resulting in enhanced RAR target gene transcription. 
 
1-4  RAR/RXR HETERODIMER AND ITS IMPLICATIONS IN 
CANCER 
  Retinoid-mediated activation of the RAR/RXR heterodimer and 
subsequent activation of target gene transcription play critical roles in the 
development and homeostasis of virtually all vertebrate tissues. The 
regulatory effects of RAR are accomplished through modulating cell 
differentiation, proliferation, and apoptosis.  
  Inhibition of cell growth results from a number of different cellular 
processes, including cell differentiation, which is accompanied by a cell 
cycle exit. When cells exit the cell cycle and enter the stage known as G0, 
they no longer divide. Instead, they may undergo differentiation to serve 
their intended purposes within the organism. In some instances, cells 
receive signals to re-enter the cell cycle and proliferate. Cancer cells, 
however, are characterized by inappropriate cell division even in the 
presence of differentiation signals. They lack the ability to sense these 
signals in order to exit the cell cycle and differentiate, and continue to go 
through cell cycle repeatedly. A better understanding of the mechanism 10 
 
by which cells decide to enter or exit the cell cycle would provide 
significant benefits to human cancer research. 
  Another mechanism through which cells can accomplish growth 
inhibition is by controlling the cell cycle (Vermeulen et al., 2003; Levine, 
1997). The cell cycle is divided into three phases consisting of G1, S, and 
G2/M, with G0 accounting for non-cycling cells. G1 is a phase in which 
cells commit to DNA replication in S phase before the cell division that 
occurs in G2/M phase. There exist many checkpoints within the cell cycle. 
In response to DNA damage, checkpoints serve to arrest the cell cycle in 
order to provide time for DNA repair. DNA damage checkpoints are 
positioned before the cell enters S phase (G1 to S checkpoint) or after 
DNA replication (G2 to M checkpoint). Further, there appear to be other 
checkpoints during S and M phases. These checkpoints involve different 
proteins that regulate the cell cycle such as cyclins, cyclin-dependent 
kinases and their inhibitors, and tumor suppressor proteins (p53 and pRb). 
These proteins have been shown to contain inactivating mutations in 
human cancers. The cell cycle, therefore, presents a complex array of 
regulating processes which could serve as a point of interest for studying 
mechanisms of cancer, the unrestrained proliferation of cells. 
  Lastly, cells can accomplish growth inhibition simply by 
undergoing programmed cell death, also called apoptosis. Apoptosis is a 
specific type of cell death, which describes, in a sequential manner, 
shrinkage of the cell, hypercondensation of chromatin, cleavage of 
chromosomes into nucleosomes, violent blebbing of the plasma 
membrane, and packaging of cellular contents into membrane-enclosed 
vesicles called ‘apoptotic bodies’ (Shi, 2001). Apoptosis is executed by a 11 
 
family of cysteine proteases that cleave their substrates after an aspartate 
residue. The cleavage activates the substrates which then go on to 
ultimately cleave a number of cellular targets leading to cell death (Shi, 
2001). The significance of apoptosis recently gained attention as an 
important contributor to cancer.  
    In most RA-sensitive tumor cells, RA causes inhibition of cell 
growth, resulting from different combinations of the three cellular 
processes discussed above: cell differentiation, cell cycle arrest, and 
apoptosis (Strickland and Mahdavi, 1978; Battle et al., 2001; Breitman et 
al., 1980; Altucci et al., 2001). In mammary carcinoma, the focus of this 
study, RA has been shown to mediate its growth inhibitory effect through 
cell cycle arrest, apoptosis, or both (Elstner et al., 1998; Toma et al., 
1998; Mangiarotti et al., 1998). Therefore, RA presents itself as an 
efficacious cancer therapy. The biological functions of RA are primarily 
exerted through its ability to induce target gene transcription via RAR in 
the form of a RAR/RXR heterodimer. However, limited information is 
currently available as to direct target genes that mediate the 
antiproliferative activities of RAR. Three such genes were reported to be 
involved in RA-induced apoptosis and differentiation in NB4 
promyelocytic leukemia cells, namely, ubiquitin-activating enzyme E1-
like protein (UBE1L), CCAAT/enhancer binding protein ε (C/EBPε), and 
TRAIL (Altucci et al., 2001; Kitareewan et al., 2002; Park et al., 1999). 
  The RAR isotype RARβ is also an RAR target gene. In several 
cancer cells, a strong correlation has been demonstrated between the 
ability of cells to increase RARβ levels upon RA treatment and RA-
dependent growth inhibition (Soprano et al., 2004). In RA-sensitive 12 
 
cancer cells, an increase in RARβ expression was observed upon RA 
treatment as opposed to the RA-resistance cancer cells that failed to 
elevate RARβ level. Overexpression of RARβ in the RA-resistant cells 
rescued the ability of these cells to inhibit growth upon RA treatment. 
These findings further suggest that RAR signaling indeed plays a key role 
in inhibiting growth of cancer cells. Therefore, there still exists the need 
to identify and further characterize direct target genes of RAR in order to 
fully elucidate the mechanism by which RA induces growth inhibition in 
the mammary carcinoma MCF-7 cells.  
 
1-5  CELL CYCLE ARREST IN G1 
  One of the key check points in the cell cycle resides in G1. There 
exist many regulatory proteins in G1 that control cell cycle progression. 
Two tumor suppressor proteins are extensively studied for their role in the 
control of G1 to S progression: pRb (retinoblastoma protein) and p53. pRb 
is a nuclear phosphoprotein whose phosphorylation state oscillates during 
the cell cycle. The hypophosphorylated form predominates in G0 and G1, 
while its hyperphosphorylated form exists in S and G2/M phases 
(Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989). The 
primary biological role of its hypophosphorylated form is to serve as a 
check point in late G1 phase. The hypophosphorlyated pRb associates 
with members of the E2F family of transcription factors and prevents their 
ability to initiate transcription, thereby leading to a cell cycle block in G1. 
In contrast, when pRb becomes phosphorylated, it releases E2Fs allowing 
them to transactivate genes required for G1 to S progression (LaThangue 
et al., 1994; Sanchez and Dynlacht, 1996; Weinberg, 1995). 13 
 
  Cyclin-dependent kinases (CDKs) are responsible for pRb 
phosphorylation. Each CDK has its own functional specificity based on 
the period of activity during the cell cycle and on the specific cyclin 
partner. D-type cyclins predominate during G1 phase to associate with 
appropriate CDKs to activate their ability to phosphorylate the target 
proteins including pRb. The expression of D-type cyclins and their ability 
to assemble with respective CDKs are heavily dependent on stimulation 
by growth factors (Sherr, 1995; Sherr, 1996). When the stimulation for 
growth ceases, the expression of D-type cyclins has been shown to 
decrease dramatically with consequent impairment of S-phase entry 
(Pagano et al., 1992; Baldin et al., 1993). 
  A further level of cell cycle control is mediated by another member 
of the tumor suppressor protein family. Unlike pRb, p53 is a transcription 
factor that enhances the rate of transcription of its target genes, which are 
involved in DNA damage repair, cell cycle arrest, and apoptosis (Levine, 
1997). These target genes, therefore, contain p53-dependent, cis-acting, 
DNA-responsive elements. p21 is one of the p53-induced target genes that 
binds to CDKs to directly inhibit their function, resulting in cell cycle 
arrest (Levine, 1997). More specifically, p21 binds to CDK4, a partner of 
cyclin D1 in G1 phase. The inhibition conferred by p21 on CDK4 prevents 
the assembly with cyclin D1, thereby preventing pRb phosphorylation. 
The hypophosphorylated pRb, then associates with E2Fs to prevent their 
transcription of target genes involved in G1 to S progression. GADD45 
and Bax are other known p53-inducible genes that are involved in DNA 
repair and apoptosis respectively (Levine, 1997). With the pleiotrophic 14 
 
effects of p53, it can be appreciated how p53 has become the center of 
intensive study for human cancers. 
  Recently, B-cell translocation gene, member 2 (BTG2) has been 
shown to be stimulated by p53 as well as by another transcription factor, 
nuclear factor kappa B (NF-κB) in breast cancer (Kawakubo et al., 2004). 
The promoter of BTG2 indeed has been shown to contain several putative 
binding sites for p53, NF-κB, and other transcription factors (Duriez et al., 
2002). BTG2 is a member of the PC3 family. The function of BTG2 was 
originally identified through studies of neural differentiation induced in 
the rat PC12 cell line by nerve growth factor (Guardavaccaro et al., 1999). 
Subsequently, the antiproliferative activity of this protein has been 
demonstrated in other cells (Kawamura-Tsuzuku et al., 2004). In NIH 3T3 
cells, overexpression of PC3 has been shown to induce accumulation of 
the hypophosphorylated form of pRb, leading to G1 arrest (Guardavaccaro 
et al., 1999). The arrest could be reversed upon coexpression of cyclin D1, 
but not by cyclin A or E. Indeed, PC3 expression was found to decrease 
the expression levels of cyclin D1 transcript and protein and to repress 
cyclin D1 promoter activity. Cyclin D1 serves the critical role in 
activating kinase activity of its partner CDK, which leads to pRb 
phosphorylation. Subsequently, the phosphorylated pRb releases the 
growth inhibitory effect on E2Fs, thereby resulting in G1 to S progression. 
Taken together, these findings pointed to an important role of PC3 as an 
anti-proliferative gene through reduction of cyclin D1 expression, which 
inhibits pRb function to arrest cells in G1.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2-1 Cell  Line. MCF-7 cells were a gift from Dr. Zhen Fan (M.D. 
Anderson Cancer Center of the University of Texas, Houston, Texas). 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS). 
 
2-2 Ligand. trans-retinoic acid (RA) was purchased from CalBiochem 
and stored at -80˚C. A fresh dilution of RA was prepared in ethanol for 
each experiment. 
 
2-3  Oligonucleotide and primers. A 95 bp oligonucleotide, containing 
the putative BTG2 RARE, was synthesized with Hind III and Bam HI 
restriction site overhangs at 5’ and 3’-ends, respectively, and PAGE-
purified (www.idtdna.com). The oligonucleotide was used to perform 
Electrophoretic Mobility Shift Assay (EMSA) directly or cloned into tk-
luciferase reporter vector using the restriction sites for transactivation 
assays. All primers used in this study were synthesized by 
www.idtdna.com.  
 
2-4 Antibodies. The following antibodies were used to perform 
chromatin immunoprecipitation: rabbit IgG (Santa Cruz 2027), RAR 
(Santa Cruz 773), RARα (Santa Cruz 551), and RXRα (Santa Cruz 553). 
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2-5 Proteins. Recombinant histidine-tagged RARα and RXRα lacking 
the amino terminal A/B domains (RARαΔAB and RXRαΔAB) were gifts 
from Leslie Donato and Rubina Yasmin respectively (Cornell University, 
Ithaca, NY). Both proteins were expressed in E. coli and purified as 
previously described (Kersten et al., 1996). 
 
2-6  Luciferase Reporter Construct. 1 μg of tk-luciferase reporter 
vector was digested with Hind III and Bam HI restriction enzymes 
(Promega) and purified using the gel extraction kit (Qiagen). The 95 bp 
oligonucleotide was subcloned into the luciferase reporter vector using T4 
ligase. The construct was verified by automated DNA sequencing 
performed at Cornell Biotechnology Center, Ithaca, NY.  
 
2-7  Fluorescence Activated Cell Sorter (FACS). MCF-7 cells were 
seeded in 6-well plates (120,000 cells per plate) in DMEM containing 
10% FBS and grown overnight. Cells were treated with RA in DMEM 
containing 1% FBS for 24 or 72 hours prior to incubation at 37˚C with 5’-
Bromo-2’-deoxyuridine (Sigma B5002) at a final concentration of 30 
μg/ml for 20 minutes. The media, two PBS washes, and trypsinized cells 
were collected into the same conical tube. A cell pellet was obtained after 
a quick spin (1,000 rpm, 5 min, room temperature (RT)). The pellet was 
then resuspended in 1 ml of PBS, rapidly injected into 10 ml of 70% 
ethanol stored at -20˚C, and incubated overnight at 4˚C. Cells were then 
centrifuged (2,500 rpm, 5 min, 10 ºC) and the supernatant aspirated. To 
the pellet, 1 ml of 2N HCl/Triton X-100 was added and incubated at room 
temperature for 30 minutes to denature the DNA. Cells were again 17 
 
centrifuged (2,500 rpm, 5 min, RT) and the supernatant aspirated. To the 
pellet, 1 ml of 0.1M Na2B4O7·10H2O at pH 8.5 was added to neutralize 
the acid. Cells were centrifuged as above to obtain the pellet to which 1 
ml of dilution buffer (0.5% Tween 20 and 1% BSA in PBS) was added. 
To the cell suspension, anti-BrdU FITC antibody (Becton Dickinson 
Catalog No. 347583) at 20 μl per 10
6 cells was added and incubated at 
room temperature for 30 minutes. Stained cells were washed with 5 ml of 
dilution buffer and resuspended in 1 ml of PBS containing 5 μg/ml of 
propidium iodide (Sigma P4864). The stained cells were sent to 
Biomedical Sciences Flow Cytometry Core Laboratory at Cornell 
University, Ithaca, NY to obtain percentages of cells in different phases of 
cell cycle according to their FITC and PI signals. 
 
2-8  Chromatin Immunoprecipitation (ChIP). MCF-7 cells were 
seeded in three 100 mm plates (2,000,000 cells per plate) and grown to 
confluency. Proteins were cross-linked to DNA (10% formaldehyde, 20 
min, 37˚C) for 20 minutes and the reaction was quenched by glycine 
(125mM, 5 min, 4˚C). Cells were washed twice with PBS, scraped, lysed 
(1% SDS, 10mM EDTA, 50mM Tris at pH 7.9, 1mM DTT, and protease 
inhibitors (Roche 1836153)), and incubated on ice for 45 minutes. Lysed 
cells were then sonicated to obtain average DNA fragment size between 
300 to 700 bp (10 sec on and 1 min off cycle twice at 27% power). At this 
point, some of the sonicated materials (1/5 volume of samples used in IP) 
were stored at 4˚C as an input. The rest were diluted (0.5% Triton X-100, 
2mM EDTA, 20mM Tris at pH 7.9, 150mM NaCl, 1mM DTT, protease 
inhibitors, salmon sperm DNA) and pre-cleared for 1 hour at 4˚C with 18 
 
protein A beads. After a quick spin, the supernatant was transferred to 
new tubes and 3.5 μg of appropriate antibodies were added and incubated 
overnight at 4˚C. The next day, protein A beads were added and incubated 
(2 hours, 4 ºC) to immunoprecipitate antibodies bound to chromatin. 
Beads were washed three times in wash buffer (0.25% NP-40, 0.05% 
SDS, 2mM EDTA, 20mM Tris at pH 8.0, 250mM NaCl, leupeptin, and 
aprotinin) and once in TE buffer. Beads were then resuspended in elution 
buffer (100mM NaHCO3, 1% SDS) and incubated for 4 hours at 65˚C to 
reverse cross-link proteins from DNA. Proteins were digested with 
Proteinase K for 1 hour and the DNA was purified using a nucleotide 
removal kit (Qiagen). The putative RARE containing region in the BTG2 
promoter was amplified by PCR using the forward primer of 5’-
cccggctacactgtatattgacttgg-3’ and the reverse primer of 5’-
gggtttcatcacgttggtcaggat-3’. 
 
2-9 Transactivation  assays. MCF-7 cells were seeded in 12-well 
plates (75,000 cells per well) in DMEM containing 10% FBS and grown 
overnight. Cells were then transfected using Fugene (Roche) in DMEM 
containing 1% FBS with 400 ηg of tk-luciferase reporter vector 
containing BTG2 RARE and 300 ηg of pCH110. After an overnight 
incubation, cells were treated with RA in serum-free DMEM for 24 hours 
and lysed. Luciferase activity was measured using the luciferase assay 
system (Promega) and corrected for transfection efficiency by β-
galactosidase activity. 
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2-10  Quantitative Real Time PCR. Total RNA was extracted using a 
RNeasy kit (Qiagen). From the RNA, cDNA was generated using 
GeneAmp RNA PCR (Applied Biosystems). Real-Time PCR was 
performed on the cDNA in quadruplicates using TaqMan chemistry and 
Assays on Demand probes (Applied Biosystems) for B-cell translocation 
gene 2 (Hs00198887_m1) and cyclin D1 (Hs00277039_m1). 18S 
ribosomal RNA (4319413E-0312010) was used as a loading control. 
Analysis was carried out using the relative standard method (Applied 
Biosystems Technical Bulletin No. 2). 
 
2-11 Electrophoretic  Mobility Shift Assay (EMSA). The 95 bp 
oligonucleotide containing BTG2 RARE was end-labeled with [
32P]-
dCTP by filling in fragments with Klenow and free nucleotides were 
removed with the nucleotide removal kit (Qiagen). The labeled probe (~1 
ηg) was incubated with 100 ηM of appropriate receptors for 20 minutes at 
room temperature in HEDGK buffer (10mM Hepes at pH 8.0, 0.1mM 
EDTA, 0.4mM DTT, 100mM KCl, 15% glycerol). In the competition 
assays, either the cold competitor DNA (unlabeled probe) or a 95 bp 
oligonucleotide of the same sequence with BTG2 RARE mutated to 
GGAGGGcgAGGGGGagAGAGGG was introduced at an increasing dose 
(100 to 800 ηg) along with the labeled probe DNA and receptors. Protein-
DNA complexes were resolved on 5% polyacrylamide gel and visualized 
by autoradiography. 
 
2-12  Affymetrix Expression Array. The array conditions and results 
were provided by Leslie Donato (Cornell University, Ithaca, NY). 20 
 
Iobion’s Gene traffic was used to perform Robust Multi-Chip Analysis 
(RMA) and cluster genes with similar activity by summary function. An 
unpaired t-test giving p values of <0.1 were defined as significantly 
changed and reported. 
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CHAPTER THREE 
RESULTS 
 
3-1  MCF-7 cells arrest in G1 in response to RA.  
  Previous studies have demonstrated that human mammary 
carcinoma cells increase the G1 cell population and apoptosis upon RA 
treatment (Elstner et al., 1998; Toma et al., 1998; Mangiarotti et al., 
1998). To verify that indeed MCF-7 cells respond to RA by arresting in 
G1, cells were treated with vehicle or 1 μM of RA for either 24 or 72 
hours prior to incubation with BrdU. BrdU becomes selectively 
incorporated into replicating DNA of cells in S phase. Then, cells were 
incubated with an anti-BrdU FITC antibody to stain BrdU in nucleus. In 
addition, propidium iodide (PI) was used to stain the entire DNA content 
of cells. PI stain differentiates between cells in G1 with DNA content of 
1X versus cells in G2/M with DNA content of 2X. A Fluorescence-
Activated-Cell Sorter (FACS) was used to sort cells according to their 
FITC and PI signals and the percentage of cell population in each phase 
was calculated and analyzed. As shown in Figure 3-1, MCF-7 cells 
increased their cell population in G1 by ~10% with 1 μM RA by 24 hours 
and this increase was further enhanced to ~15% after 72 hours. The cell 
population in apoptosis was also increased at both 24 and 72 hours after 
RA treatment. The increase of cell population in G1 corresponded to the 
decrease in S and G2/M phases. Hence, in agreement with previous 
findings, RA prevented the cells from undergoing G1 to S transition, 
thereby arresting cells in G1. 
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A) 
 
 
 
 
 
 
 
 
 
 
B) 
 
 Sub  G1  G1  S G2/M 
vehicle-24 hrs 
RA-24 hrs 
 
vehicle-72 hrs 
RA-72 hrs 
4.5 ± 0.6 
10.0 ± 2.2 
 
0.73 ± 0.2 
8.1 ± 1.4 
30.0 ± 0.6 
39.0 ± 3.3 
 
41.0 ± 1.2 
56.0 ± 1.1 
48.0 ± 1.5 
38.0 ± 1.8 
 
45.0 ± 3.9 
25.0 ± 0.7 
16.0 ± 0.8 
11.0 ± 0.7 
 
12.0 ± 2.0 
9.4 ± 1.4 
* mean ± standard deviation, n=3 
 
 
Figure 3-1 MCF-7 cells arrest in G1 in response to RA. A) MCF-7 
cells were treated with vehicle or RA (1 μM) for 24 or 72 hours prior to 
incubation with BrdU for 20 minutes. Cells were then fixed in ethanol and 
double-stained with both anti-BrdU FITC antibody and propidium iodide 
(PI). FACS was used to sort cells in different phases of cell cycle 
according to their FITC and PI signal. B) % of total cells in each phase is 
presented.  
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3-2  RA induces expression of cell cycle regulating genes in MCF-7 
cells. 
  Affymetrix Expression Array data was provided by Leslie Donato 
(Cornell University, Ithaca, NY). Data were collected as follows: MCF-7 
cells were treated with vehicle or 50 ηM RA for 4 hours and total RNA 
isolated. Probes were generated and hybridized to Affymetrix human 
U133 A/B arrays, monitoring more than 40,000 genes and ESTs. The 
differences in the gene expression profiles between untreated and RA-
treated cells were analyzed. Changes in gene expression were observed in 
triplicate for each condition and the genes with p values of <0.1 (unpaired 
t-test) were considered significant. RA induced genes were clustered by 
similar biological functions using the GeneTraffic software system 
(Iobion).  
Several genes that are known to be involved in cell cycle regulation 
were identified (Table 3-1). Among these, B-cell translocation gene, 
member 2 (BTG2) known to function in G1 to S progression, displayed a 
prominent RA-induced increase in expression. RA responsive genes can 
be directly regulated by RAR through an RA response element in their 
promoters. Alternatively, these genes can be indirectly regulated by other 
direct target genes of RAR. With limited information on RA-responsive 
genes that are directly regulated by RAR, it became pertinent to 
investigate BTG2 as a direct target of RAR that arrests MCF-7 cells in G1 
phase. 24 
 
 
 
 
 
 
 
 
Table 3-1 MCF-7 cells induce cell cycle regulating genes in response 
to RA. MCF-7 cells were treated with vehicle or RA (50 ηM) for 4 hours. 
Affymetrix Expression Array was used to compare the mRNA expression 
of untreated versus treated cells. Fold inductions of genes involved in cell 
cycle regulation are presented. 
 
Gene  Fold activation Known function 
B-cell translocation gene 2 2.3 ± 0.1  G1/S transition 
Prostaglandin E synthase  1.6 ± 0.0  induce p53 expression 
E2F transcription factor 3  1.3 ± 0.1  specifically binds to pRb 
Cyclin-dependent kinase 8 1.3 ± 0.1  cell cycle progression 
Cyclin E2  1.2 ± 0.0  interact with CDK inhibitors
* mean ± standard deviation, n=3 
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3-3  BTG2 expression is upregulated in response to RA.  
  To verify the array data, TaqMan Real-Time PCR was carried out 
to quantitate the mRNA level of BTG2. Data were normalized to 18S 
rRNA. MCF-7 cells were treated with 50 ηM RA for 4 hours, lysed, and 
total RNA extracted. cDNA was generated from the RNA and Real-Time 
PCR was used to quantitate BTG2 mRNA level (Figure 3-2). In good 
agreement with the Affymetrix data, RA treatment increased BTG2 level 
by ~4 fold. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 BTG2 mRNA level is upregulated in response to RA. 
MCF-7 cells were treated with vehicle or RA (50 ηM) for 4 hours, then 
lysed for total RNA. cDNA was synthesized from the total RNA and used 
to measure BTG2 mRNA level by TaqMan Real-Time PCR. The reading 
was normalized to 18S rRNA level and fold activation is presented.  
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 3-4  BTG2 is a direct target of RAR.  
  To determine whether BTG2 is a direct target for RAR, the effect 
of cycloheximide treatment on BTG2 level was examined. Cycloheximide 
is an inhibitor for protein synthesis, but it does not affect transcriptional 
activity of genes that do not depend on new protein synthesis. Cells were 
pre-treated with cycloheximide for 10 minutes, then treated with 50 ηM 
RA for indicated time periods (4 hours for caspase-7 and 30 minutes for 
BTG2). Cells were lysed to obtain total RNA which was used to generate 
cDNA. TaqMan Real-Time PCR was performed on the cDNA to 
quantitate BTG2 mRNA expression level normalized to 18S rRNA. The 
analysis (Figure 3-3) showed that inhibition of protein synthesis did not 
hinder RA-induced upregulation of BTG2 expression, demonstrating that 
this gene is directly regulated by RAR. Caspase-7, which has been 
previously shown to be an indirect target of RAR (Donato and Noy, 
2005), was used in this analysis as a negative control. Unlike with BTG2, 
upregulation of caspase-7 in response to RA was completely abolished 
upon cycloheximide treatment, indicating that caspase-7 requires 
secondary responses of RAR. 
 27 
 
 
  A) 
  
 
 
 
 
 
 
 
 
 
 
 
 
  B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3 BTG2 mRNA upregulation in response to RA is not 
affected by cycloheximide. A) MCF-7 cells were pre-treated with 
cycloheximide (20 μg/ml) for 10 minutes, then treated with RA (50 ηM) 
for 4 hours in the presence of cycloheximide. Caspase-7 (negative 
control) mRNA level was measured with TaqMan Real-Time PCR and 
normalized to 18S rRNA. Fold activation is presented. B) Same treatment 
condition was followed as in A) to measure BTG2 mRNA level except 
that cells were treated with RA for 30 minutes.  
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3-5  CRABP II further enhances BTG2 upregulation by RA.  
  Previous studies demonstrated that CRABP II directly delivers RA 
from the cytosol to RAR in the nucleus, thereby enhancing the 
transcriptional activity of the receptor (Budhu and Noy, 2002). These 
observations suggest that the RA-induced upregulation of direct RAR 
target genes will be enhanced by CRABP II. Indeed, it was previously 
shown that CRABP-II enhances RA-induced upregulation of another 
direct RAR target gene, caspase-9 (Donato and Noy, 2005).  Therefore, it 
was of an interest to investigate the effect of CRABP II overexpression on 
the expression BTG2 in the absence and presence of RA. 
  MCF-7 cells were transfected with an expression vector encoding 
CRABP-II for 24 hours, then treating with vehicle or RA for 4 hours. The 
mRNA level of BTG2 was then examined by TaqMan Real-Time PCR. 
Figure 3-4 shows that RA treatment upregulated BTG2 expression by 
~2.2 fold. With CRABP II overexpression, BTG2 expression was further 
enhanced to ~3.0 fold. Notably, CRABP II overexpression alone did not 
increase the expression of BTG2, indicating that CRABP II does not 
regulate BTG2 independently of RA. 
 29 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 CRABP II overexpression further enhances BTG2 mRNA 
level in response to RA. MCF-7 cells were transfected with either an 
empty vector (pSG5) or a CRABP II expression vector. Cells were treated 
with vehicle or RA (50 ηM) for 4 hours, then processed for TaqMan Real-
Time PCR to measure BTG2 mRNA level. The reading was normalized 
to 18S rRNA level and fold activation is presented.  
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3-6  A functional RARE is present in the promoter of BTG2.  
  Consensus RAREs consist of two direct hexameric repeats of 
PuG(G/T)TCA spaced by either 2 or 5 bp, DR2 and DR5 respectively. 
TransFac (www.gene-regulation.com) was used to screen 4,000 bp 
upstream of the transcription start site of BTG2 for putative RAREs. 
DR2s consisting of three half sites were detected at 3,250 bp upstream of 
the start site (Figure 3-5). The putative BTG2 RARE sequence is as 
follows: GGATCAcgAGGTCAagAGATCA. This element along with 
flanking sequences on both sides (95 bp in length) was used to perform 
EMSA to determine if RARα and RXRα can bind to the RARE in vitro.  
  RAR and RXR lacking their N-terminal A/B domain (RARαΔAB 
and RXRαΔAB) were provided by Leslie Donato and Rubina Yasmin 
respectively. These proteins, fused with a hexahistidine tag, were 
expressed in E. coli using the bacterial expression vector pET18, and 
purified by affinity chromatography (Kersten et al., 1996). The 95 bp 
oligonucleotide containing BTG2 RARE was end-labeled with [
32P]-
dCTP by filling in fragments with Klenow, and used as a probe in the 
experiment. The labeled probe (~1 ηg) was incubated with 100 ηM of 
appropriate receptor proteins for 20 minutes at room temperature in 
HEDGK buffer. In the competition assays, either the cold competitor 
DNA (unlabeled probe) or a 95 bp oligonucleotide of the same sequence 
with a mutated BTG2 RARE was introduced at an increasing dose (100 to 
800 ηg) along with the labeled probe DNA and receptors. Protein-DNA 
complexes were resolved on 5% polyacrylamide gel and visualized by 
autoradiography.  31 
 
  The data (Figure 3-6C: Lane 1-4) showed that RAR and RXR bind 
to the RARE as a heterodimer. Competition assay was performed with 
increasing amounts of the cold probe to observe that the intensity of the 
heterodimer band decreased in a dose-dependent manner (Figure 3-6C: 
Lane 5-8). In contrast, addition of increasing amounts of the mutated 
RARE (Figure 3-6C: Lane 9-12) did not inhibit DNA binding by the 
heterodimer. Taken together, the data demonstrated that RAR and RXR as 
a heterodimer specifically binds to the BTG2 RARE in vitro.  
 Next,  chromatin  immunoprecipitation assay (ChIP) was performed 
to determine if RAR/RXR heterodimer binds to the BTG2 RARE in cells. 
Proteins were cross-linked to chromatin in MCF-7 cells, sonicated, then 
immunoprecipitated using antibodies for IgG, RAR, and RXR. Finally, 
the crosslink was reversed, DNA isolated, and a 200 bp region flanking 
the BTG2 RARE was amplified by PCR. The data (Figure 3-7) showed 
that antibodies for RAR or RXR precipitated the putative BTG2 RARE, 
indicating that the RARE is occupied by the heterodimers in cells. 
  Since RAR/RXR heterodimer binds to the putative RARE both in 
vitro and in cells, the functionality of the element was examined by 
transactivation assays performed in MCF-7 cells. First, the 95 bp 
oligonucleotide containing the element used in EMSA was cloned into the 
tk-luciferase reporter vector. This vector was transfected into MCF-7 cells 
along with an expression vector for β-galactosidase and incubated 
overnight. Cells were then treated with RA for 24 hours prior to lysis. Cell 
lysates were used to measure the luciferase activity and the measurements 
were normalized to β-galactosidase activity. The luciferase activity from a 
vector containing the element, as expected, displayed RA-dose 32 
 
responsiveness (Figure 3-8). These observations showed that the response 
element found in BTG2 promoter indeed binds RAR/RXR heterodimers 
in cells and that the element comprises a functional RARE, as 
demonstrated by its RA dose-responsiveness. Hence, BTG2 is a direct 
target for RAR signaling. 
 
 
 
 
 
 
 
 
5’- 
TACATTAAGTTTCCTCTCCCTAGGCTTGTGTATAGAAAGAAAAG
AGGAGAGGCTGGGCACAATGGCTCATGCCTGTAATCCCAGCAC
TTTGGGAAGCCAAGGTGGGTGGATCACGAGGTCAAGAGATCA
AGACCATCCTGACCAACGTGATGAAACCCCACCTCTACTAAAA
ATACAAAAATAGCTGGGCATGGTGGTGCATGCCTGCAGTCCCA
GCTACTCGGGAGGCTGAAGCAG     
-3’ 
 
Figure 3-5 BTG2 upstream sequence from -3,357 to -3,142 bp with 
respect to transcription start site. The sequence contains three RARE 
half sites starting at -3,250 bp. RAREs are boldfaced and underlined. 
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A) 
AGCTTTCTAATCCCAGCACTTTGGGAAGCCAAGGTGGGTGGAT
CACGAGGTCAAGAGATCAAGACCATCCTGACCAACGTGATGA
AACCCCACCG 
B) 
AGCTTTCTAATCCCAGCACTTTGGGAAGCCAAGGTGGGTGGAG
GGCGAGGGGGAGAGAGGGAGACCATCCTGACCAACGTGATG
AAACCCCACCG 
 
C) 
 
 
Figure 3-6 RAR-RXR heterodimer binds to BTG2 RARE in vitro. A) 
95 bp oligonucleotide sequence containing BTG2 RARE and the flanking 
region. RAREs are boldfaced and underlined. B) 95 bp oligonucleotide 
sequence containing mutated BTG2 RARE and the flanking region. 
Mutated RAREs are boldfaced and underlined. C) EMSA was carried out 
using bacterially expressed RARαΔAB (100 ηM), RXRαΔAB (100 ηM), 
and the oligonucleotide (1 ηg) from A) as a radioactive-labeled probe. 
Lanes (1-4): None; RAR alone; RXR alone; RAR and RXR together. 
Lanes (5-8): Both RAR and RXR in all lanes with increasing amounts of 
cold oligonucleotide from A) (100, 200, 400, and 800 ηg respectively). 
Lanes (9-12): Both RAR and RXR in all lanes with increasing amounts of 
cold mutated oligonucleotide from B) (100, 200, 400, and 800 ηg 
respectively).    
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Figure 3-7 RAR-RXR heterodimer binds to BTG2 RARE in vivo. A) 
MCF-7 cells were fixed with 1% formaldehyde prior to lysis. Cells were 
then sonicated to obtain DNA fragment size between 300 and 700 bp, 
which served as an input. The remaining chromatin was 
immunoprecipitated with appropriate antibodies as indicated. PCR was 
performed on the immunoprecipitated materials to amplify the BTG2 
RARE containing region as shown in B). 
 BTG2 RARE  
 -3’   5’- 
Primer (26 bp) 
-3,447 to -3,421 
Primer (26 bp) 
-3,223 to -3,197 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8 BTG2 RARE is RA-dose responsive. The 95 bp 
oligonucleotide containing BTG2 RARE and the flanking region 
(sequence shown in Figure 3-6A) was cloned into a tk-luciferase reporter 
vector. MCF-7 cells were transfected with the reporter vector and an 
expression vector for β-galactosidase. Cells were then treated with 
increasing doses of RA (from 0 ηM to 100 ηM) for 24 hours prior to 
measurement of luciferase activity. Luciferase activity was normalized to 
β-galactosidase activity and fold activation is presented. 
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3-7  RA downregulates the cyclin D1 mRNA expression. 
  Previous studies demonstrated that BTG2 confers its anti-
proliferative activity through downregulating cyclin D1 expression. Since 
the data so far have demonstrated that BTG2 is a direct target of RAR and 
that its expression upregulated by RA, it became of an interest to examine 
whether cyclin D1 expression responds to RA. Figure 3-9 showed that 
cyclin D1 expression was indeed downregulated by ~50% in response to 1 
μM RA treatment for 24 hours. As cyclin D1 is not a direct target for 
RAR, the data strongly suggest that BTG2 induction by RA leads to 
decrease in cyclin D1 expression, thereby arresting cells in G1 phase. 
 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9 Cyclin D1 mRNA level is downregulated in response to 
RA. MCF-7 cells were treated with vehicle or RA (1 μM) for 24 hours, 
then processed for TaqMan Real-Time PCR to measure cyclin D1 mRNA 
level. The reading was normalized to 18S rRNA level and fold activation 
is presented. 
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CHAPTER FOUR 
DISCUSSION 
 
  RA displays a growth inhibitory effect on human mammary 
carcinoma cells through apoptosis, cell cycle arrest, or both (Elstner et al., 
1998; Toma et al., 1998; Mangiarotti et al., 1998), rendering RA as a 
sensible agent for a breast cancer therapy. However, the exact mechanism 
of inhibition and the genes involved in the growth inhibition are poorly 
understood. The present study was undertaken to identify target genes 
responsible for RA-induced, RAR-mediated cell cycle arrest, and the 
contribution of CRABP II to the process. 
  The initial FACS data (Figure 3-1) demonstrated that RA treatment 
induced cell cycle arrest in the G1 phase as shown by the increase in 
percentage of cells in G1 and the corresponding decrease in S and G2/M 
phases. This is in agreement with previous studies. In this experiment, the 
percentage of cells in each phase was analyzed after 24 and 72 hours 
following a 24 hour pretreatment with 1 μM RA.  RA-sensitive cells, 
however, have been shown to display a high rate of RA metabolism. For 
example, in MCF-7 cells, 1 μM RA was metabolized to its polar 
metabolites with a corresponding decrease in RA to a trace amount after 
only ~5 hours (van der Leede et al., 1997). According to this reported 
rate, RA used in this experiment degrades rapidly. However, the 
percentage of cells in G1 was further increased by about 15% after 72 
hours compared to 24 hours post the 24 hour RA pretreatment. These 
observations suggest that RA triggers cellular pathways that remain active 
even long after the pretreated RA has been completely metabolized. 39 
 
RA exerts its action through RAR by activating the transcription of 
target genes. Therefore, it became important to examine RA-responsive 
genes that might be involved in cell cycle regulation. Several RA-
responsive genes were identified that control the G1 to S transition (Table 
3-1). Among them, B-cell translocation gene, member 2 (BTG2) 
displayed the most prominent induction in its expression upon 4 hour 
treatment with RA (Figure 3-2). At this short time period, it can be 
reasonably expected that some of these genes are direct targets of RAR. In 
Figure 3-3, MCF-7 cells were pretreated with cycloheximide prior to RA 
treatment. Cycloheximide stops new protein synthesis, thereby negating 
any secondary effects from other RA-responsive proteins. The data 
showed that the upregulation of BTG2 expression by RA was unaffected 
by cycloheximide treatment, indicating that BTG2 is indeed directly 
regulated by RAR (Figure 3-3B). In contrast, cycloheximide abolished the 
RA effect on caspase-7, a known indirect target of RAR, as it depends on 
RA to upregulate the expression of direct RAR target genes, which in turn 
induce caspase-7 expression (Figure 3-3A).  
  The RA action depends on CRABP II in addition to RAR. The 
previous studies demonstrated that CRABP II binds to RA and directly 
associates itself with RAR, thereby allowing RA to be channeled to RAR. 
Therefore, CRABP II expression can further enhance the effect of RA on 
direct target genes of RAR. The data (Figure 3-4) showed that CRABP II 
overexpression indeed further enhanced BTG2 expression in the presence 
of RA, indicating once again that BTG2 is a direct target of RAR. In 
addition, it should be noted that transfection efficiency of MCF-7 cells 
with Fugene is relatively low. Therefore, the effect of CRABP II on 40 
 
BTG2 expression in this study is an underestimation as not all cells are 
expressing CRABP II. Lastly, CRABP II expression alone did not 
enhance the basal level of BTG2 expression. This demonstrates that 
CRABP II does not have a function of its own in regulating BTG2 
expression. Instead, CRABP II cooperates with RAR in activating 
transcription of BTG2. The observations thus far demonstrate that BTG2 
is an endogenous gene that is under the direct control of RAR. 
  As a possible direct target of RAR, 4,000 bp upstream from the 
start site of BTG2 was screened for potential RAREs. At 3,250 bp 
upstream of the start site, a putative RARE was located (Figure 3-5). The 
RARE has three half sites spaced by 2 bp. An EMSA was performed to 
confirm that RAR and RXR together bind to the element (Figure 3-6: 
Lane 1-4). The binding was further tested with both a wild-type and a 
mutant cold competitor. The binding to the element by RAR and RXR 
together decreased in a dose-dependent manner with the wild-type 
competitor (Figure 3-6: Lane 5-8). In contrast, the binding was not 
affected by the mutant competitor (Figure 3-6: Lane 9-12). These 
observations demonstrate that the RAR/RXR heterodimer binds to the 
element in vitro. The binding was further examined with chromatin 
immunoprecipitation (ChIP) to show that both RAR and RXR bind to the 
element in MCF-7 cells (Figure 3-7). Lastly, the functionality of the 
element was tested by RA-induced transcription of a luciferase reporter 
vector. The element along with the flanking regions on both sides (95 bp 
in length) was cloned into the vector and used in a transactivation assay. 
The element responded to RA in a dose-dependent fashion (Figure 3-8). 41 
 
Taken together, the RARE located at 3,250 bp upstream of the start site of 
BTG2 binds RAR/RXR heterodimer and is RA-dose responsive. 
  The findings demonstrate that BTG2 is a direct target of RAR, 
which is involved in arresting MCF-7 cells in G1 phase. The downstream 
targets of BTG2, therefore, became of interest to examine. Several studies 
have previously reported that BTG2 represses the transcription of cyclin 
D1, a critical protein in cell cycle regulation. Cyclin D1 serves to activate 
cyclin-dependent kinase (CDK). The activation induces the kinase activity 
of CDK to phosphorylate pRb, a G1 checkpoint protein. The 
phosphorylated form of pRb then releases E2Fs, members of the family of 
transcription factors that activate transcription of genes involved in G1 to 
S transition. This release, therefore, allows for the cell cycle progression. 
Consequently, cyclin D1 expression, when reduced, plays an important 
role in arresting cells in G1 phase. Therefore, the cyclin D1 expression 
level was examined to understand the mechanism by which BTG2 induces 
cell cycle arrest. The data demonstrated that RA induced the decrease in 
cyclin D1 expression in MCF-7 cells by ~50% (Figure 3-9). This suggests 
that BTG2, a novel direct target of RAR reported in this study, induces 
cell cycle arrest by decreasing cyclin D1 expression. Interestingly, 
previous studies of possible effects of RA on cyclin D1 expression in 
other cell lines such as human bronchial epithelial cells and lymphomas 
indicated that cyclin D1 expression was not RA-responsive (Ma et al., 
2005; Guidoboni et al., 2005). Therefore, the data presented here in MCF-
7 cells are the first demonstration of RA regulating cyclin D1 expression. 
  Taken together, the findings described here demonstrate that, in 
MCF-7 cells, RA induces cell cycle arrest in G1 phase by directly 42 
 
regulating BTG2 expression through RAR, and that CRABP II 
participates in further upregulation of BTG2 expression. The data further 
indicate that the most downstream target of RA-induced growth inhibition 
through this path is cyclin D1 whose expression is, in turn, downregulated 
by BTG2. This decrease in cyclin D1 expression prevents G1 to S 
transition, thereby arresting MCF-7 cells in G1. These findings are 
summarized in Figure 3-10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10 The RA signaling pathway results in cell cycle arrest.  
 
  As for future directions, the rate of RA degradation can be 
investigated in MCF-7 cells to ascertain the effect of RA on the initiation 
of cellular pathways. In this study, RA enhanced its effect on cell cycle 
arrest with corresponding increase in the treatment time. This observation 
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suggests that RA can trigger a growth inhibitory pathway in MCF-7 cells 
that can remain active in the absence of a constant supply of RA to the 
cells. Quantitative measurements of RA concentrations in cells can help to 
pinpoint a time course during which the effect of RA persists after RA has 
metabolized to a basal physiological level.    
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